A tandem-repeat variant of the frog antimicrobial peptide PGLa called DiPGLa-H showed the strongest antibacterial activity among nine variants, improved mouse survival by 31–38% in infection models, and can be produced cost-effectively at scale.
100–1,000× bacterial reductionDiPGLa-H reduced bacterial burdens in mouse organs by 100 to 1,000-fold while improving survival by 31–38% in a peritoneal infection model
What the researchers found
DiPGLa-H, a tandem-repeat variant of the frog-derived antimicrobial peptide PGLa, achieved a therapeutic index of 35.94 — meaning it kills bacteria at concentrations far below those that harm host cells. It was effective against E. coli, Staphylococcus aureus, and Acinetobacter baumannii, and disrupted biofilms formed by multiple pathogenic species.
In mouse peritoneal inflammation models, DiPGLa-H improved survival rates by 31–38% and reduced bacterial burdens in key organs by 100-fold to 1,000-fold. The peptide works by disrupting both inner and outer bacterial membranes, causing cell shrinkage, vesiculation, and intracellular content leakage.
A DAMP4 fusion protein strategy combined with non-chromatographic purification achieved high-purity biosynthesis with yields of 21.2 mg/mL, enabling cost-effective large-scale production.
Why it matters
Antibiotic resistance is one of the biggest threats to global health, and antimicrobial peptides are among the most promising alternatives. However, most AMPs fail clinically because they are too weak, too toxic, or too expensive to produce. This study addresses all three problems: DiPGLa-H is potent and selective, safe for mammalian cells, and can be manufactured cost-effectively. The systematic comparison of nine variants also provides valuable structure-activity relationship data for designing future AMPs.
How the study worked
The researchers designed and synthesized nine variants of PGLa and characterized their structure (all retained α-helical conformations), biocompatibility (hemolysis and macrophage toxicity assays), and antimicrobial activity (minimum inhibitory concentration testing against key pathogens). They assessed membrane disruption mechanisms using microscopy and leakage assays. Biofilm disruption was tested against multiple species. In vivo efficacy was evaluated in a mouse peritoneal inflammation model, measuring survival rates and organ bacterial burdens. A DAMP4 fusion protein approach with acid cleavage and non-chromatographic purification was developed for scalable production.
What this study cannot tell us
The in vivo testing was limited to a mouse peritoneal inflammation model, which may not represent all clinical infection scenarios. Long-term toxicity, pharmacokinetics, and resistance development were not assessed. The study did not test DiPGLa-H against a comprehensive panel of clinical multidrug-resistant isolates. Stability in human biological fluids (serum, wound fluid) was not specifically evaluated, though pH and temperature stability were demonstrated.
How to read the evidence
This is a preclinical study combining in vitro characterization, mechanistic analysis, and in vivo mouse infection models. The systematic comparison of nine variants and the inclusion of both efficacy and safety data strengthen the evidence, but clinical translation remains unproven.
When this study was published
Published in 2025, this is a very recent study reflecting current advances in antimicrobial peptide engineering and biosynthesis technology.
The bigger picture
Amphibian-derived antimicrobial peptides have been studied for decades, but translating them into clinical drugs has been stymied by potency, safety, and manufacturing challenges. This study represents a significant step forward by combining rational peptide engineering (tandem-repeat design), rigorous safety testing, in vivo efficacy demonstration, and a scalable production method — the full pipeline needed to advance an AMP toward clinical application against multidrug-resistant infections.
Questions still open
- How does DiPGLa-H perform against a broader panel of multidrug-resistant clinical isolates, including MRSA and carbapenem-resistant Enterobacteriaceae?
- What are the pharmacokinetics and potential for resistance development with repeated DiPGLa-H exposure?
- Could DiPGLa-H be developed as a topical treatment for wound infections or as a systemic antibiotic alternative?
Common questions
What makes DiPGLa-H different from natural antimicrobial peptides?
Why are antimicrobial peptides considered a promising alternative to antibiotics?
Read the original research
Antimicrobial peptide DiPGLa-H exhibits the most outstanding anti-infective activity among the PGLa variants based on a systematic comparison.
Applied and environmental microbiology, 91(3), e0206224
Citation
Zheng, Liangjun; Zafir, Muhammad; Zhang, Ziqian; Ma, Yadong; Yang, Fengyi; Wang, Xiaokun; Xue, Xuemei; Wang, Chen; Li, Ping; Liu, Pilong; El-Gohary, Fatma A; Zhao, Xin; Xue, Huping. (2025). Antimicrobial peptide DiPGLa-H exhibits the most outstanding anti-infective activity among the PGLa variants based on a systematic comparison.. Applied and environmental microbiology, 91(3), e0206224. https://doi.org/10.1128/aem.02062-24